Next, wound-healing assays revealed that CD133+ cells were capable of significantly faster wound closure than CD133– cells (Fig. 2g), and a transwell assay with Matrigel demonstrated that CD133+ cells were more invasive than CD133– cells (Fig. 2h), indicating the higher metastatic capacity of CD133+ cells (as cell-migration ability is required for cancer metastasis) [25]. This evidence concerns the gene PROM1 and cancer.